News & Updates

Faces of Lung Cancer Report
Reflection of COVID-19. The annual report is now available!
Read More


The Fundraising Complex

“It was almost like you have to say, ‘By the way, it wasn’t his fault that he got this disease.’” - Maria Amaral

Lung is the deadliest cancer, accounting for one-quarter of cancer deaths by killing 20,000 Canadians each year — more than breast, colorectal and prostate cancers combined. But it doesn’t get a run for a cure or a dedicated day when professional athletes wear dedicated colours to raise awareness.

Yet when it comes to Canadian research funding the numbers are flipped. Lung cancer receives about six per cent, while breast cancer gets more than a quarter of dollars raised.

Volunteer Week

Lung Cancer Canada is celebrating Volunteer Week by thanking Canada’s 12.7 million #volunteers! We've had the pleasure of working with many GREAT volunteers who give up their time to help support lung cancer patients, their families and promote lung cancer awareness.  For that we say THANK YOU!!

INESSS in Quebec Approves Opdivo as Exceptional Drug Status

Immunotherapy Opdivo (nivolumab) has been approved with Exceptional Drug Status in Quebec for the treatment of NSCLC!

Lung Cancer Connection - Winter 2017

Winter may be officially over (finally!) but check out LCC's Lung Cancer Connection Winter 2017 Newsletter!

pERC Issues Positive FINAL Recommendation for Zykadia

Today, the pCODR Expert Review Committee (pERC) issued the Final Recommendation for ceritinib (Zykadia) resubmission for NSCLC.  pERC recommends reimbursement of ceritinib (Zykadia) monotherapy for patients with ALK positive locally NSCLC.

This is more great news for lung cancer patients!  Lung Cancer Canada encourages the pan-Canadian Pricing Alliance (pCPA) to begin negotiations as soon as possible so that patients are not left waiting for much needed therapy.

Ontario Latest Province to Cover Cost of Immuno-Oncology Treatment OPDIVO® (nivolumab)

Bristol-Myers Squibb Canada Co. (BMS Canada) today announced that Cancer Care Ontario and the Ontario Ministry of Health and Long-Term Care have agreed to cover the cost of the immuno-oncology treatment OPDIVO® for three different difficult-to-treat tumour types, effective March 20, 2017.

pCOCR-CADTH Releases Positive Initial Reccomendation for Tagrisso

More good news for NSCLC patients!  Both lung cancer drugs Tagrisso (osimertinib) and Zykadia (ceritinib) received positive initial recommendations from pCODR-CADTH.

Major Step Forward in Accessing New Life-Extending Medication

Major Step Forward in Accessing New Life-Extending Medication for Advanced Metastatic Lung, Melanoma and Kidney Cancer Patients.

Canadian lung, melanoma and kidney cancer patients are one step closer to gaining access to immunotherapy after pCPA negotiations have concluded. Provinces and Territories are encouraged to list quickly.

CCO is Introducing a Lung Cancer Screening Pilot

Cancer Care Ontario is introducing a lung cancer screening pilot program for people at high risk in April 2017.

Stakeholder Briefing

New Research Shows Canadian Lung Cancer Patients Are Disadvantaged Compared to Their US Peers and Shocking Trends Among Women

Displaying results 71-80 (of 107)
 |<  <  2 - 3 - 4 - 5 - 6 - 7 - 8 - 9 - 10 - 11  >  >|